Cargando…

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China

BACKGROUND: High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. Since 2017, China has implemented national price negotiations for medicines, relying on evidence from health technology assessments. We aim to assess the relation betwee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yichen, Wei, Yuxuan, Li, Huangqianyu, Chen, Yixuan, Guo, Yiran, Han, Sheng, Shi, Luwen, Guan, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270265/ https://www.ncbi.nlm.nih.gov/pubmed/35764914 http://dx.doi.org/10.1007/s40273-022-01161-7

Ejemplares similares

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data
por: Yang, Yu, et al.
Publicado: (2023)

The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China
por: Bao, Yuwen, et al.
Publicado: (2023)

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
por: Mingge, Xia, et al.
Publicado: (2023)

Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review
por: He, Zixuan, et al.
Publicado: (2023)

Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study
por: Guan, Xiaodong, et al.
Publicado: (2019)

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis
por: Huang, Cong, et al.
Publicado: (2021)

Using strategic price negotiations to contain costs and expand access to medicines in China
por: Si, Lei, et al.
Publicado: (2020)

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study
por: Cai, Lele, et al.
Publicado: (2022)

Negotiating prices of drugs for rare diseases
por: Henrard, Séverine, et al.
Publicado: (2016)

Payer-Negotiated Prices for Telemedicine Services
por: Wu, Shannon S., et al.
Publicado: (2022)

Comparison of US Hospital Cash Prices and Commercial Negotiated Prices for 70 Services
por: Jiang, John (Xuefeng), et al.
Publicado: (2021)

A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
por: Guan, Xiaodong, et al.
Publicado: (2018)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
por: Wu, Di, et al.
Publicado: (2022)

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021
por: Bai, Lin, et al.
Publicado: (2023)

Impact of house price growth on mental health: Evidence from China
por: Wei, Guoxu, et al.
Publicado: (2020)

Effect of the full coverage policy of essential medicines on medication adherence: A quasi-experimental study in Taizhou, China
por: Guo, Zhigang, et al.
Publicado: (2022)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
por: Rawson, Nigel S. B.
Publicado: (2022)

Effects of the Full Coverage Policy of Essential Medicines on Inequality in Medication Adherence: A Longitudinal Study in Taizhou, China
por: Guo, Zhigang, et al.
Publicado: (2022)

Smith’s paradox of price and negotiation: Empirical evidence from India
por: Dey Biswas, Sattwick
Publicado: (2021)

China and Weapons of Mass Production: The "China Price" Is the "Cheating Price
por: Navarro, Peter
Publicado: (2010)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2012)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2015)

Comparison of Commercial Negotiated Price and Cash Price Between Physician-Owned Hospitals and Other Hospitals in the Same Hospital Referral Region
por: Wang, Yang, et al.
Publicado: (2023)

Price wars and price collusion in China's airline markets
por: Zhang, Yahua, et al.
Publicado: (2011)

Pharmacy Benefit Manager Pricing and Spread Pricing for High-Utilization Generic Drugs
por: Mattingly, T. Joseph, et al.
Publicado: (2023)

Enhancing medicine price transparency through price information mechanisms
por: Hinsch, Michael, et al.
Publicado: (2014)

PRICE'S TEXTBOOK OF MEDICINE
Publicado: (1956)

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis
por: Sun, Yan, et al.
Publicado: (2022)

The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis
por: Ding, Yi, et al.
Publicado: (2022)

Factors Associated With Hospital Commercial Negotiated Price for Magnetic Resonance Imaging of Brain
por: Jiang, John Xuefeng, et al.
Publicado: (2023)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

The impacts of implementation of National Essential Medicines Policies on primary healthcare institutions: a cross-sectional study in China
por: Guo, Zhigang, et al.
Publicado: (2017)

Access to Paediatric Essential Medicines: A Survey of Prices, Availability, Affordability and Price Components in Shaanxi Province, China
por: Wang, Xiao, et al.
Publicado: (2014)

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
por: Jiang, Di Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bs2hq94git6c49souf25chtcac